Form 4: Cryoport Director Sells Over 10,000 Shares Under Pre-Arranged Trading Plan

Cryoport, Inc. Director Ramkumar Mandalam has reported the sale of 10,712 shares of common stock over three days in June 2025, reducing his beneficial ownership to 66,377 shares.

Summary

• Cryoport, Inc. Director Ramkumar Mandalam reported the sale of common stock through a series of transactions.
• On June 11, 2025, Mr. Mandalam sold 8,193 shares of common stock at a weighted average price of $7.0567 per share, with prices ranging from $7.00 to $7.05.
• On June 12, 2025, an additional 1,895 shares were sold at a weighted average price of $7.0113 per share, with prices ranging from $7.00 to $7.03.
• On June 13, 2025, 624 shares were sold at a price of $6.8047 per share.
• The total number of shares sold across these three days is 10,712.
• Following these transactions, Mr. Mandalam's direct beneficial ownership of Cryoport common stock stands at 66,377 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan, indicating the sales were scheduled in advance.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director reducing their stake, although mitigated by the presence of a 10b5-1 plan. The declining sale price over the period also contributes to a slightly cautious sentiment.

Positives

• The sales were conducted under a Rule 10b5-1(c) trading plan, which suggests the transactions were pre-scheduled and not based on immediate, non-public information, potentially mitigating negative market perception.

Negatives

• A director reducing their stake in the company, even under a pre-arranged plan, can sometimes be perceived as a lack of confidence or a need for liquidity.
• The sale price for the shares decreased over the three-day period, from a weighted average of $7.0567 on June 11 to $6.8047 on June 13.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is an insider transaction report and does not provide broader industry context or trends. It reflects an individual director's stock activity rather than a company-wide strategic move.

Stakeholder Impact

• Shareholders may view the reduction in a director's stake with caution, potentially interpreting it as a signal about future company performance or the director's personal financial needs.
• The market might react to the insider selling, potentially influencing short-term stock price movements.

Key Dates

Keywords

Cryoport, CYRX, Form 4, Insider Trading, Stock Sale, Director, Ramkumar Mandalam, 10b5-1 Plan